DGX Form 4: Director adds 6 shares via DRIP; holds 2,698
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Quest Diagnostics (DGX) director Robert B. Carter reported acquiring 6 shares of common stock on 10/21/2025 at $189.089 per share. The shares were obtained through a dividend reinvestment plan eligible for deferred reporting on Form 5 under Rule 16a-6; the transaction was reported early.
After this transaction, Carter beneficially owns 2,698 shares, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
CARTER ROBERT B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 6 | $189.089 | $1K |
Holdings After Transaction:
Common Stock — 2,698 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did DGX report?
A director, Robert B. Carter, acquired 6 shares of common stock.
When did the DGX insider transaction occur?
The transaction date was 10/21/2025.
What was the Form 4 transaction code for DGX?
The transaction code was A (acquired).
Was the DGX purchase under a plan?
Yes. The shares were acquired via a dividend reinvestment plan and were eligible for deferred reporting under Rule 16a-6.
Who signed the DGX Form 4 and when?
Signed by Sean D. Mersten, Attorney-in-Fact for Robert B. Carter, on 10/24/2025.